Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials

2016 ◽  
Vol 60 ◽  
pp. 154-165 ◽  
Author(s):  
Massimo Gentile ◽  
Katja Zirlik ◽  
Stefania Ciolli ◽  
Francesca R. Mauro ◽  
Nicola Di Renzo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Controlled Clinical Trials ◽  
Front Line ◽  
Practice Experience ◽  
Line Therapy

Trends in randomized controlled trials in ENT: a 30-year review

1997 ◽  
Vol 111 (7) ◽  
pp. 611-613 ◽  
Author(s):  
K. W. Ah-See ◽  
N. C. Molony ◽  
A. G. D. Maran
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Randomized Controlled Trials ◽  
Gold Standard ◽  
Controlled Trials ◽  
Evidence Based ◽  
Controlled Clinical Trials ◽  
Medline Search ◽  
Randomized Controlled Clinical Trials ◽  
Randomized Controlled

AbstractThere is a growth in the demand for clinical practice to be evidence based. Recent years have seen a rise in the number of randomized controlled clinical trials (RCTS). Such trials while acknowledged as the gold standard for evidence can be difficult to perform in surgical specialities. We have recently identified a low proportion of RCTS in the otolaryngology literature. Our aim was to identify any trend in the number of published RCTS within the ENT literature over a 30-year period and to identify which areas of our speciality lend themselves to this form of study design. A Medline search of 10 prominent journals published between 1966 and 1995 was performed. Two hundred and ninety-six RCTS were identified. Only five were published before 1980. Two hundred (71 per cent) of RCTS were in the areas of otology and rhinology. An encouraging trend is seen in RCTS within ENT literature.

scholarly journals Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

2019 ◽  
Vol 20 (11) ◽  
pp. 1576-1586 ◽  
Author(s):  
Carmen D Herling ◽  
Kevin R Coombes ◽  
Axel Benner ◽  
Johannes Bloehdorn ◽  
Lynn L Barron ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Time To Progression ◽  
Front Line

scholarly journals Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

2019 ◽  
Vol 12 (2) ◽  
pp. 69 ◽  
Author(s):  
Daniel A. Rodrigues ◽  
Fernanda S. Sagrillo ◽  
Carlos A. M. Fraga
Keyword(s):  
Clinical Trials ◽  
Follicular Lymphoma ◽  
Chronic Lymphocytic Leukaemia ◽  
Drug Administration ◽  
Small Molecule ◽  
Lymphocytic Leukaemia ◽  
Food And Drug Administration ◽  
Small Lymphocytic Lymphoma ◽  
Dual Inhibitor ◽  
Systemic Therapies

Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.

Sign in / Sign up

Export Citation Format

Share Document